Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025

Core Points - Cellectis, a clinical-stage biotechnology company, will hold its annual general meeting on June 26, 2025, at 2:30 p.m. CET in Paris, France [1] - The company specializes in developing life-saving cell and gene therapies using its gene-editing platform [2][3] - Cellectis employs an allogeneic approach for CAR T immunotherapies, focusing on off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire value chain [2] Company Information - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [3] - The company is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [3] - For more information, Cellectis provides contact details for media and investor relations [4]